Article ID Journal Published Year Pages File Type
5824527 Clinical Therapeutics 2015 12 Pages PDF
Abstract
Based on the findings from this study in patients with opioid dependence, the higher-bioavailability BNX sublingual tablet formulation was noninferior to both generic buprenorphine (induction) and BNX film (stabilization). These findings suggest that BNX sublingual tablets are an efficacious and well-tolerated option for induction and early stabilization treatment of opioid dependence. ClinicalTrials.gov identifier: NCT01908842.
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Authors
, , , ,